May 13, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
May 09, 2025
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
May 08, 2025
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 28, 2025
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
Apr 24, 2025
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Apr 07, 2025
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
Mar 27, 2025
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
Feb 20, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
Feb 12, 2025
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Feb 05, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
Dec 17, 2024
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
Oct 24, 2024
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
Oct 18, 2024
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
Aug 27, 2024
Theravance Biopharma to Participate in an Upcoming Investor Conference
May 13, 2024
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
Theravance Biopharma to Participate in an Upcoming Investor Conference
Apr 29, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Apr 10, 2024
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Feb 22, 2024
Theravance Biopharma to Participate in an Upcoming Investor Conference
Feb 14, 2024
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024